Jianmin Pharmaceutical Group Co Ltd (600976) - Total Liabilities
Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) has total liabilities worth CN¥1.92 Billion CNY (≈ $281.42 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Jianmin Pharmaceutical Group Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Jianmin Pharmaceutical Group Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Jianmin Pharmaceutical Group Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Jianmin Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jianmin Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
China | CN¥136.87 Million |
|
President Bakery Public Company Limited
BK:PB
|
Thailand | ฿1.13 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩39.81 Billion |
|
Reitir fasteignafélag hf
IC:REITIR
|
Iceland | Ikr174.57 Billion |
|
Guangzhou KingTeller Technology Co Ltd
SHE:002177
|
China | CN¥25.84 Million |
|
Anpec Electronics
TWO:6138
|
Taiwan | NT$1.74 Billion |
|
Shanghai Shenda Co Ltd
SHG:600626
|
China | CN¥6.51 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600976 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jianmin Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jianmin Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total liabilities of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.81 Billion ≈ $264.23 Million |
-1.18% |
| 2024-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
-4.40% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.71 Million |
+21.76% |
| 2022-12-31 | CN¥1.57 Billion ≈ $229.71 Million |
+24.85% |
| 2021-12-31 | CN¥1.26 Billion ≈ $183.99 Million |
+14.94% |
| 2020-12-31 | CN¥1.09 Billion ≈ $160.07 Million |
+51.80% |
| 2019-12-31 | CN¥720.63 Million ≈ $105.45 Million |
+24.87% |
| 2018-12-31 | CN¥577.11 Million ≈ $84.45 Million |
-29.34% |
| 2017-12-31 | CN¥816.71 Million ≈ $119.51 Million |
+5.18% |
| 2016-12-31 | CN¥776.45 Million ≈ $113.62 Million |
+28.40% |
| 2015-12-31 | CN¥604.72 Million ≈ $88.49 Million |
+11.00% |
| 2014-12-31 | CN¥544.79 Million ≈ $79.72 Million |
+7.90% |
| 2013-12-31 | CN¥504.92 Million ≈ $73.89 Million |
+41.08% |
| 2012-12-31 | CN¥357.90 Million ≈ $52.37 Million |
+22.87% |
| 2011-12-31 | CN¥291.28 Million ≈ $42.62 Million |
+27.32% |
| 2010-12-31 | CN¥228.78 Million ≈ $33.48 Million |
-51.91% |
| 2009-12-31 | CN¥475.79 Million ≈ $69.62 Million |
+19.61% |
| 2008-12-31 | CN¥397.80 Million ≈ $58.21 Million |
+178.04% |
| 2007-12-31 | CN¥143.07 Million ≈ $20.94 Million |
-49.83% |
| 2006-12-31 | CN¥285.18 Million ≈ $41.73 Million |
-5.36% |
| 2005-12-31 | CN¥301.33 Million ≈ $44.09 Million |
+37.36% |
| 2004-12-31 | CN¥219.38 Million ≈ $32.10 Million |
-9.46% |
| 2003-12-31 | CN¥242.31 Million ≈ $35.46 Million |
+25.34% |
| 2002-12-31 | CN¥193.32 Million ≈ $28.29 Million |
+17.27% |
| 2001-12-31 | CN¥164.85 Million ≈ $24.12 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.